Table 2.
Differences in immunostaining
| Absent | Sparse | Moderately dense | Dense | p-value | ||
|---|---|---|---|---|---|---|
| S100 | Patients with BE | 0 (0) | 15 (44.1) | 10 (29.4) | 9 (26.5) | 0.210 |
| Patients with VUR | 0 (0) | 1 (16.7) | 2 (33.3) | 3 (50.0) | ||
| NF200 | Patients with BE | 10 (29.4) | 15 (44.1) | 5 (14.7) | 4 (11.8) | 0.197 |
| Patients with VUR | 1 (16.7) | 1 (16.7) | 3 (50.0) | 1 (16.7) | ||
| CGRP | Patients with BE | 20 (58.8) | 7 (20.6) | 3 (8.8) | 4 (11.8) | 0.897 |
| Patients with VUR | 3 (50.0) | 2 (33.3) | 1 (16.7) | 0 (0) | ||
| TH | Patients with BE | 3 (8.8) | 15 (44.1) | 10 (29.4) | 6 (17.6) | 0.956 |
| Patients with VUR | 0 (0) | 2 (50.0) | 3 (50.0) | 0 (0) | ||
Observation of S100, NF200, CGRP, and TH in biopsies obtained from 34 patients with bladder exstrophy (BE) during primary closure and from 6 patients with congenital vesicoureterorenal reflux (VUR) during reflux surgery who served as controls. The table shows the frequency and, in brackets, the percentage